685886-34-4

Upstream product

• 475174-71-1 7-bromo-2-ethyl-3-nitropyrazolo[1,5-a]pyridine 
• 475174-68-6 7-bromo-2-ethylpyrazolo[1,5-a]pyridine 
• 475174-64-2 1-(but-1-yn-1-yl)pyridine 
• 685886-88-8 tert-butyl N-(7-bromo-2-ethylpyrazolo[1,5-a]pyridin-3-yl)-N-cyclopropylmethylcarbamate 
• 685886-45-7 7-bromo-2-ethylpyrazolo[1,5-a]pyridine-3-amine 
• 685886-47-9 7-bromo-N-(cyclopropylmethyl)-2-ethylpyrazolo[1,5-a]pyridin-3-amine 
• 475174-67-5 N-amino-2-(1-butynyl)pyridinium mesitylenesulfonate 
• 109-04-6 2-bromo-pyridine 
• 685885-75-0 N-(cyclopropylmethyl)-7-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-2-ethyl-N-[(tetrahydro-2H-pyran-4-yl)methyl]pyrazolo[1,5-a]pyridin-3-amine 
• 104-15-4 toluene-4-sulfonic acid 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor

Design, synthesis, and structure-activity relationships of a series of 3-dialkylamino-7-phenyl pyrazolo[1,5-a]pyridines (I) as selective antagonists of the corticotropin-releasing factor 1 (CRF1) receptor are described. The most prominent compound to emerge from this work, 46 (E2508), exhibits potent in vitro activity, excellent drug-like properties, and robust oral efficacy in animal models of stress-related disorders. It has advanced into clinical trials.

Process for production of pyrazole-fused ring derivatives

An object of the invention is to find out intermediates usful for the synthesis of pyrazol-fused ring derivatives (such as 7-phenylpyrazolo[1,5-a]pyridine derivatives) and a method for producing the same. A method for producing compound represented by the general formula (II), wherein Z1 and Z2 each independently represents a methine group or a nitrogen atom; R1 represents an ethyl group or the like; R5 represents a hydrogen atom or the like; R2 and R3 each independently represents a C1-6 alkyl group or the like, salts thereof, or solvates of both, comprising the step of: reacting a compound represented by the general formula (I), wherein Z1, Z2, R5, R1, R2 and R3 each has the same definition as described above, with an organometallic reagent; and then reacting the resulting product with pentafluoroiodobenzene. [image]